SBIR Phase I: Treatment of Type 2 Diabetes through Cryoablation of the Duodenum

SBIR 第一阶段：通过十二指肠冷冻消融治疗 2 型糖尿病

• 批准号: 2321818
• 负责人: Peter Garcia-Meza
• 金额: $ 27.5万
• 依托单位: AGIL THERAPEUTICS, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2024
• 资助国家: 美国
• 起止时间: 2024-02-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2321818&HistoricalAwards=false
• 关键词: SBIR; Phase; Treatment; Type; Diabetes

This Small Business Innovation Research Phase (SBIR) I project is a novel procedural treatment for the 5-10 million people in the U.S. with medical refractory Type 2 Diabetes. Current treatments require self-management of insulin injections and/or medication, frequent visits to specialists, and a controlled diet. Patients can fail to achieve optimal glycemic control due to the individual medication dosing requirements, safety, and tolerance limits. Poorly managed patients can suffer from adverse events including heart attack, stroke, nerve damage, blindness, and early death. This Duodenal Cryoablation system aims to provide an outpatient, minimally invasive procedure for controlled ablation of the duodenum utilizing a standard, cost-effective endoscopic approach. If successful, the novel therapy will decrease or eliminate insulin and/or medical therapies in patients suffering from medical refractory Type 2 Diabetes. This SBIR Phase I project aims to develop a novel cryoablation system that delivers a highly controlled and targeted cryoablative agent for freezing the duodenum. The system is based on emerging evidence of duodenum remodeling upon ablation resulting in restoration of glucose control and regulation. The technical engineering milestones include managing high pressures of the cryogenic fluid within extreme dimensions including small luminal diameters and long length, within a unique and tortuous path. A key objective is to produce a system ensuring consistent cryogenic fluid delivery down a small diameter, insulated, long length lumen to a set of sprayers placed in the duodenum. A second objective is the development of a method of consistent cryogenic fluid distribution through the sprayers to the target tissue. The final objective is the development of bench methods and testing capabilities validating consistent cryogenic fluid delivery. The design will be tested in preclinical models and the harvested tissue evaluated via histopathological analysis for ablation efficacy.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小型企业创新研究阶段（SBIR）I项目是一种新的程序性治疗方法，用于美国5- 1000万难治性2型糖尿病患者。目前的治疗需要自我管理胰岛素注射和/或药物治疗，经常去看专家，以及控制饮食。 由于个体药物剂量要求、安全性和耐受性限制，患者可能无法实现最佳血糖控制。管理不善的患者可能会发生不良事件，包括心脏病发作、中风、神经损伤、失明和过早死亡。该十二指肠冷冻消融系统旨在提供一种门诊微创手术，利用标准的、具有成本效益的内窥镜方法对十二指肠进行受控消融。如果成功，新疗法将减少或消除患有医学难治性2型糖尿病的患者的胰岛素和/或药物疗法。该SBIR I期项目旨在开发一种新型冷冻消融系统，该系统提供高度受控和靶向的冷冻消融剂用于冷冻十二指肠。该系统基于消融后十二指肠重塑的新证据，导致葡萄糖控制和调节恢复。技术工程里程碑包括在极端尺寸（包括小管腔直径和长长度）内，在独特而曲折的路径内管理低温流体的高压。一个关键目标是生产一种系统，确保低温流体沿着小直径、绝缘、长长度管腔持续输送到放置在十二指肠中的一组喷雾器。第二个目的是开发一种通过喷雾器向目标组织均匀分配低温流体的方法。最终目标是开发台架方法和测试能力，以验证低温流体输送的一致性。该设计将在临床前模型中进行测试，并通过组织病理学分析对采集的组织进行消融效果评估。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。